Pre-order Enquiry
Request Free Sample
Global Acenocoumarol Market Insights, Forecast to 2028
SKU ID : QYR-20154848 | Publishing Date : 08-Feb-2022 | No. of pages : 107
Request Sample
Request Customization
Check Discounts
Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist (like warfarin). It is a derivative of coumarin and is generic, so is marketed under many brand names worldwide.
Market Analysis and Insights: Global Acenocoumarol Market
Due to the COVID-19 pandemic, the global Acenocoumarol market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 1 mg accounting for % of the Acenocoumarol global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Coronary Occlusions segment is altered to an % CAGR throughout this forecast period.
China Acenocoumarol market size is valued at US$ million in 2021, while the US and Europe Acenocoumarol are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Acenocoumarol landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Acenocoumarol include Novartis, Mylan, Teva, Merus Labs, Abbott, Aurobindo, Neiss Labs, Polfa Warszawa and Macleods, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Acenocoumarol Scope and Segment
Acenocoumarol market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Acenocoumarol market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
1 mg
2 mg
4 mg
Segment by Application
Coronary Occlusions
Pulmonary Embolism
Systemic Embolism
Transient Ischaemic Attack (TIA)
Others
By Company
Novartis
Mylan
Teva
Merus Labs
Abbott
Aurobindo
Neiss Labs
Polfa Warszawa
Macleods
PharmaSwiss
Sun Pharma
Alkaloida
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Market Analysis and Insights: Global Acenocoumarol Market
Due to the COVID-19 pandemic, the global Acenocoumarol market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the review period. Fully considering the economic change by this health crisis, 1 mg accounting for % of the Acenocoumarol global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Coronary Occlusions segment is altered to an % CAGR throughout this forecast period.
China Acenocoumarol market size is valued at US$ million in 2021, while the US and Europe Acenocoumarol are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Acenocoumarol landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period.
The global key manufacturers of Acenocoumarol include Novartis, Mylan, Teva, Merus Labs, Abbott, Aurobindo, Neiss Labs, Polfa Warszawa and Macleods, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Acenocoumarol Scope and Segment
Acenocoumarol market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Acenocoumarol market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
1 mg
2 mg
4 mg
Segment by Application
Coronary Occlusions
Pulmonary Embolism
Systemic Embolism
Transient Ischaemic Attack (TIA)
Others
By Company
Novartis
Mylan
Teva
Merus Labs
Abbott
Aurobindo
Neiss Labs
Polfa Warszawa
Macleods
PharmaSwiss
Sun Pharma
Alkaloida
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
